Firebrick Pharma (FRE) Stock Price, News & Analysis

Company Overview

Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Medical Equipment
• Current Symbol: ASX:FRE
• CUSIP: N/A
• CIK: N/A
• Web: www.firebrickpharma.com
• Phone: 1300 301 874
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-1,180,000.00
• Net Margins: -42.75%
• Pretax Margin: N/A
• Return on Equity: -51.22%
• Return on Assets: -25.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.19
• Quick Ratio: 18.29

Sales & Book Value

• Annual Sales: $2.75 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 195,670,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.68